In a regulatory filing, Vir Biotechnology CEO Marianne De Backer disclosed the sale of 72,995 common shares of the company on April 3 at a price of $9.4577 per share.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIR:
- Vir Biotechnology completes Phase 2 SOLSTICE clinical trial ahead of schedule
- Biotech Alert: Searches spiking for these stocks today
- Vir Biotechnology Ends Influenza Deal with GlaxoSmithKline
- Vir Biotechnology reports Q4 EPS (86c), consensus ($1.01)
- Vir Biotechnology Announces Executive Leadership Transition
